13-48456250-C-T
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4BS2
The NM_000321.3(RB1):c.1861C>T(p.Arg621Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000663 in 1,614,138 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R621H) has been classified as Likely benign.
Frequency
Consequence
NM_000321.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
RB1 | NM_000321.3 | c.1861C>T | p.Arg621Cys | missense_variant | 19/27 | ENST00000267163.6 | |
RB1 | NM_001407165.1 | c.1861C>T | p.Arg621Cys | missense_variant | 19/27 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
RB1 | ENST00000267163.6 | c.1861C>T | p.Arg621Cys | missense_variant | 19/27 | 1 | NM_000321.3 | P1 | |
RB1 | ENST00000650461.1 | c.1861C>T | p.Arg621Cys | missense_variant | 19/27 | ||||
RB1 | ENST00000643064.1 | c.194+74807C>T | intron_variant | ||||||
RB1 | ENST00000480491.1 | n.560C>T | non_coding_transcript_exon_variant | 3/3 | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152148Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000915 AC: 23AN: 251442Hom.: 0 AF XY: 0.0000662 AC XY: 9AN XY: 135902
GnomAD4 exome AF: 0.0000684 AC: 100AN: 1461872Hom.: 0 Cov.: 31 AF XY: 0.0000605 AC XY: 44AN XY: 727230
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152266Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74452
ClinVar
Submissions by phenotype
Retinoblastoma Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 19, 2021 | DNA sequence analysis of the RB1 gene demonstrated a sequence change, c.1861C>T, in exon 19 that results in an amino acid change, p.Arg621Cys. This sequence change has been described in the gnomAD database with a frequency of 0.014% in the non-Finnish European subpopulation (dbSNP rs367578442). The p.Arg621Cys change affects a moderately conserved amino acid residue located in a domain of the RB1 protein that is not known to be functional. The p.Arg621Cys substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change does not appear to have been described in individuals with retinoblastoma, however it has been reported in an individual with breast cancer and in vitro experimental studies indicated that this variant was unable to induce apoptosis in cultured cells (PMID: 20594292). A different amino acid change at this same position, p.Arg621Ser, has been reported in a 5-month-old individual with unilateral retinoblastoma. Due to insufficient evidences, the clinical significance of the p.Arg621Cys change remains unknown at this time. - |
Hereditary cancer-predisposing syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 02, 2022 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at